Go Pro

Climb Bio (CLYM) 10K Form and Latest SEC Filings 2026

Climb Bio logo
$13.08 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$13.12 +0.04 (+0.31%)
As of 06/26/2026 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Climb Bio SEC Filings & Recent Activity

Climb Bio (NASDAQ:CLYM) has submitted 190+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Climb Bio's financial statements. The most recent filing was a Form 8-K submitted on June 12, 2026.

Form 4
Climb Bio, Inc. Reports Ownership Change on Jun. 8, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Climb Bio Files Current Report on Jun. 12, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Climb Bio Files Quarterly Report on May. 7, 2026

The 10-Q contains Climb Bio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Climb Bio SEC Filing History

Browse Climb Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
06/12/2026 3:36 PM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 6:12 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2026 11:15 PM
Climb Bio (1768446) Filer
Form EFFECT
06/09/2026 3:24 PM
Climb Bio (1768446) Filer
Form 424B3
06/08/2026 5:57 PM
Climb Bio (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:39 PM
Climb Bio (1768446) Issuer
Drapkin Kimberlee C (1340881) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:42 PM
Climb Bio (1768446) Issuer
Levin Andrew David (1867539) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:26 PM
Climb Bio (1768446) Issuer
Dunn Judith (1811904) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:28 PM
Climb Bio (1768446) Issuer
Thomas Stephen Basil (2027962) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:34 PM
Climb Bio (1768446) Issuer
Cumbo Alexander (1685994) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:37 PM
Climb Bio (1768446) Issuer
WILLIAMS DOUGLAS E (1184847) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2026 6:12 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2026 3:05 PM
Climb Bio (1768446) Filer
Form S-3
Registration statement under Securities Act of 1933  
05/07/2026 6:30 AM
Climb Bio (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2026 6:05 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/05/2026 6:45 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 5:44 PM
Climb Bio (1768446) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
04/29/2026 5:46 PM
Climb Bio (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 7:30 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 3:13 PM
Climb Bio (1768446) Filer
Form DEF 14A
04/24/2026 3:15 PM
Climb Bio (1768446) Filer
Form DEFA14A
04/24/2026 3:17 PM
Climb Bio (1768446) Filer
Form ARS
04/10/2026 3:05 PM
Climb Bio (1768446) Filer
Form PRE 14A
04/03/2026 3:05 PM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 6:20 AM
Climb Bio (1768446) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 6:30 AM
Climb Bio (1768446) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/05/2026 6:10 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 3:05 PM
ALTSCHULLER Susan (1817988) Reporting
Climb Bio (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:05 PM
Climb Bio (1768446) Issuer
Wilson Perrin Megan (2074091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:05 PM
Brennan Aoife (1714563) Reporting
Climb Bio (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 6:07 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:55 PM
Climb Bio (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2025 3:12 PM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/15/2025 6:55 PM
Climb Bio (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 6:56 PM
Climb Bio (1768446) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
12/11/2025 7:16 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 6:21 AM
Climb Bio (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 6:15 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 6:11 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2025 4:48 PM
AI ETI LLC (1871741) Filed by
Climb Bio (1768446) Subject
Form SCHEDULE 13D/A
10/07/2025 3:51 PM
AI ETI LLC (1871741) Filed by
Climb Bio (1768446) Subject
Form SCHEDULE 13D/A
SpaceX IPO hides a much bigger story (Ad)

The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel

Click here to see the details before the crowd catches on
10/01/2025 4:52 PM
ALTSCHULLER Susan (1817988) Reporting
Climb Bio (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 4:49 PM
ALTSCHULLER Susan (1817988) Reporting
Climb Bio (1768446) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/01/2025 4:23 PM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 6:48 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2025 8:26 AM
Climb Bio (1768446) Subject
Pontifax Management 4 G.P. (2015) Filed by
Form SCHEDULE 13G
08/12/2025 6:10 AM
Climb Bio (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2025 6:15 AM
Climb Bio (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/01/2025 3:32 PM
Climb Bio (1768446) Issuer
Thomas Stephen Basil (2027962) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Climb Bio SEC Filings - Frequently Asked Questions

Climb Bio (CLYM) has submitted 190+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Climb Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Climb Bio's financial statements page.

The most recent filing was a Form 8-K submitted on June 12, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CLYM) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners